延长输注β-内酰胺类抗生素的国际共识建议
该共识由临床药学与医学国际专家小组制定,针对静脉β-内酰胺类抗生素的延长(延长和持续)输注(PIs)给出治疗建议。共识涵盖药代动力学与药效学目标、治疗药物监测考虑,以及在重症与非重症成人、儿童和肥胖患者中的PI β-内酰胺治疗应用。推荐已获美国临床药学学会(ACCP)、英国抗微生物化疗学会(BSAC)、囊性纤维化基金会(CFF)、欧洲临床微生物与感染病学会(ESCMID)、美国感染病学会(IDSA)、美国重症医学会(SCCM)和感染病药师学会(SIDP)审阅与认可。这是首个关于β-内酰胺类抗生素以延长输注方式给药的共识指南。
要点
- β-内酰胺类为时间依赖性杀菌药,疗效与给药间期内游离药物浓度高于病原体最低抑菌浓度(MIC)的时间直接相关。
- 延长(延长和持续)输注可增加血药浓度高于MIC的时间,但全球实施不一致。
- 共识针对重症与非重症成人、儿童及肥胖患者给出PI β-内酰胺治疗建议,涵盖药代动力学/药效学目标与治疗药物监测。
- 推荐已获ACCP、BSAC、CFF、ESCMID、IDSA、SCCM和SIDP审阅与认可。
适用人群与场景
- 重症成人患者
- 非重症成人患者
- 儿童患者
- 肥胖患者
研究设计与关键结果
- 共识由临床药学与医学国际专家小组制定,给出关于药代动力学与药效学目标、治疗药物监测考虑及PI β-内酰胺治疗在重症与非重症成人、儿童和肥胖患者中应用的推荐。
- 推荐已获ACCP、BSAC、CFF、ESCMID、IDSA、SCCM和SIDP审阅与认可。
证据类型、等级与局限
- 证据类型:国际专家小组共识指南;已获ACCP、BSAC、CFF、ESCMID、IDSA、SCCM和SIDP认可。
对床旁实践的改变
- 原文未据此给出推荐。
指南或共识出处
- 国际延长输注β-内酰胺类抗生素使用共识建议;获ACCP、BSAC、CFF、ESCMID、IDSA、SCCM和SIDP认可。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Intravenous β-lactam antibiotics remain a cornerstone in the management of bacterial infections due to their broad spectrum of activity and excellent tolerability. β-lactams are well established to display time-dependent bactericidal activity, where reductions in bacterial burden are directly associated with the time that free drug concentrations remain above the minimum inhibitory concentration (MIC) of the pathogen during the dosing interval. In an effort to take advantage of these bactericidal characteristics, prolonged (extended and continuous) infusions (PIs) can be applied during the administration of intravenous β-lactams to increase time above the MIC. PI dosing regimens have been implemented worldwide, but implementation is inconsistent. We report consensus therapeutic recommendations for the use of PI β-lactams developed by an expert international panel with representation from clinical pharmacy and medicine. This consensus guideline provides recommendations regarding pharmacokinetic and pharmacodynamic targets, therapeutic drug-monitoring considerations, and the use of PI β-lactam therapy in the following patient populations: severely ill and nonseverely ill adult patients, pediatric patients, and obese patients. These recommendations provide the first consensus guidance for the use of β-lactam therapy administered as PIs and have been reviewed and endorsed by the American College of Clinical Pharmacy (ACCP), the British Society for Antimicrobial Chemotherapy (BSAC), the Cystic Fibrosis Foundation (CFF), the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), the Infectious Diseases Society of America (IDSA), the Society of Critical Care Medicine (SCCM), and the Society of Infectious Diseases Pharmacists (SIDP).
参考来源
- Hong LT, Downes KJ, FakhriRavari A, et al. International consensus recommendations for the use of prolonged-infusion beta-lactam antibiotics: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2023. PMID: 37615245. doi:10.1002/phar.2842
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。